# A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

> **NCT05657574** · PHASE3 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 228 (estimated)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** D377
- **DRUG:** CKD-331
- **DRUG:** D086
- **DRUG:** Placebo (for D377)
- **DRUG:** Placebo (for CKD-331)
- **DRUG:** Placebo (for D086)

## Key facts

- **NCT ID:** NCT05657574
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-24
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05657574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05657574, "A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05657574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*